Summary

First-line treatment for metastatic colorectal cancer (mCRC) is combination chemotherapy (CT) plus a monoclonal antibody (mAB). The Cetuximab and/or Bevacizumab Combined With Combination Chemo—therapy in Treating Patients With Metastatic Colorectal Cancer [CALGB/SWOG 80405; NCT00265850] study examined whether a strategy that blocked endothelial growth factor receptors with the mAB cetuximab (CET) or blocked vascular endothelial growth factors with the mAB bevacizumab (BEV) provided a greater improvement in the effectiveness of CT.